“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Create an account and get access to all information about Celcuity
No Credit card required. Free Credit
No Credit card required. It’s fast, easy, and FREE! 🛠️
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
About
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The companys lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com
| C-Level 5 | VP - Level5 |
| Director28 | Manager4 |
| Others24 | |
| Structure | Email Format |
|---|---|
| <first><l>@ |
John |
| <first>@ | John@digitcom.it |
| Pain Points | Locations | Technologies |
|---|---|---|
| Application Development | United States | communication, database, e, risk, integrity, compliance, data management, collaboration, data collection, operations |
| BI | United States | communication, database, e, risk, integrity, compliance, data management, collaboration, operations |
| Build & Release | United States | communication, database, e, risk, integrity, compliance, data management, collaboration, data collection, operations |
| Compliance | United States | communication, database, e, risk, integrity, compliance, data management, collaboration, data collection, operations |
| Database Administration | United States | communication, database, e, risk, integrity, compliance, data management, collaboration, data collection, operations |
Celcuity looking to hire in Digital Transformation in United States
Celcuity looking to hire in Embedded Design in Minneapolis, MN
Celcuity looking to hire in Compliance in United States
Gcp
Access
Acrobat
Board
Director
Agile
Analytics
Audit
Collaboration
Communication
Celcuity is a clinical-stage biotechnology company seeking a Molecular and Cellular Biology Scien...
View MoreUnder the supervision of the Senior Vice President, Clinical Development, the Medical Director wo...
View MoreJoin a High-Impact, Fast-Moving TeamAre you a master of organization, a communicator at heart, an...
View MoreReporting to Chief Medical Officer (CMO), the VP/SVP of Clinical development role involves partic...
View MoreReporting to Chief Medical Officer (CMO), the VP/SVP of Clinical development role involves partic...
View MoreCelcuity is a clinical-stage biotechnology company seeking a Molecular and Cellular Biology Scien...
View MoreIn the race to redefine advanced breast cancer treatment,. Celcuity Inc. CELC. --. (NASDAQ: CLTY) has emerged as a standout contender with Gedatolisib,
Read MoreOn July 14, 2025, Celcuity's stock surged by 17.16% in pre-market trading, marking a significant rise that has caught the attention of investors and
Read MoreMINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted
Read MoreMINNEAPOLIS - Celcuity Inc. (NASDAQ:CELC), currently valued at $516 million, announced Monday it has been granted U.S. Patent No.
Read MoreCelcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The companys lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to...
Celcuity operates in the Biotechnology industry.
Celcuity's revenue is $17.23m
Celcuity has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.